This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site



Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyOff-contract claimsAlliance Healthcare

Example content

About Zinforo

About Zinforo

OverviewExtended spectrum coverage


Adult & adolescent dosingNeonatal & paediatric dosing
Efficacy & Safety

Efficacy & Safety

EfficacyFOCUS Phase III Trial (CAP)CANVAS Phase III Trial (cSSTI)ASIA CAP Phase III TrialPaediatric EfficacyAdult safetyPaediatric Safety
Clinical & Scientific Data

Clinical & Scientific Data

Patient Risk FactorsCAP patient profilescSSTI patient profilesCAPTURE study
Support & Resources

Support & Resources

Videos & case studiesVideos

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Zinforo®: A smart choice for patients when there’s no time to waitZinforo Mode of ActionWatch the video to explore the Zinforo mode of action1

A fifth-generation cephalosporin with coverage against key causative pathogens in children with cSSTI, including MRSA, and CAP, including penicillin susceptible strains of S. pneumoniae1,2

Zinforo has relatively low protein binding (<20%), and using data comparing protein binding with rate of penetration to the site of infection, is predicted to have a rapid penetration rate3,4

A safety and tolerability profile consistent with comparator therapies in clinical studies‡§5-8 and a similar safety profile in the paediatric population to that observed in adults.II​​​​​​​

Approved to treat neonates and infants <2 months of age with a proven clinical response in paediatric patients with cSSTI and CAP.9,10​​​​​​​

Explore moreZinforo has an extended in vitro spectrum of coverage, including key pathogens in CAP and cSSTI**1-3,11 Learn more Loading

‡ Zinforo is contraindicated in patients with hypersensitivity to any active substance or excipient and should not be used in patients with a history of hypersensitivity to other cephalosporin-class antibiotics or who have had an immediate and severe hypersensitivity reaction (e.g., anaphylaxis to other ß-lactam antibacterial agents). Fatal hypersensitivity reactions are possible. Antibacterial-associated colitis and pseudomembranous colitis (Clostridium difficile) have been reported, including cases that were life-threatening. Patients with a pre-existing seizure disorder should use Zinforo with caution as seizures occurred in toxicology studies at doses higher than typical human exposures. DAGT (Coombs test) became positive in 11.2% of patients from five pooled pivotal studies in patients who received Zinforo every 12 hours and in 32.3% of patients who received Zinforo every 8 hours.1
​​​​§Comparator therapies: cSSTI, ceftriaxone; CAP, vancomycin or cefazolin, plus optional aztreonam.
IIBased on two clinical trials in 227 paediatric patients aged from 2 months to 17 years. The most common adverse reactions occurring in ≥3% of patients treated with Zinforo were diarrhoea, rash and vomiting, and were generally mild or moderate in severity.9,10
Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1


CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infections; MRSA, methicillin-resistant Staphylococcus aureus.

Prescribing Information​​​​​​​

Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 


ZINFORO. Summary of Product CharacteristicsLaudano JB. J Antimicrob Chemother 2011;66(Suppl.3):iii11-iii18Drusano GL, et al. J Antimicrob Chemother 2011;66:iii61-7Riccobene TA, et al. Antimicrob Agents Chemother 2016;60:5849-57Corey G, et al. Clin Infect Dis 2010;51:641–50Santos PD, et al. J Chemother 2013;25:341–6Corrado ML. J Antimicrob Chemother 2010;65(Suppl 4):iv67–iv71Lodise TP, Low DE. Drugs 2012;72:1473–93 Korczowski B, et al. Pediatr Infect Dis J 2016;35:e239–47Cannavino CR, et al. Pediatr Infect Dis J 2016;35:752–59Garrison MW, et al. Expert Rev Anti Infect Ther 2012;10:1087-103
PP-ZFO-GBR-0219. September 2021

Explore the outcomes of the Zinforo Phase III clinical trials in adult patients with CAP and cSSTI

Efficacy Loading
Discover specific information on the use of Zinforo in neonates, infants and children here:

Adverse events should be reported. Reporting forms and information can be found at or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2023 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-UNP-GBR-7284 November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
You are now leaving PfizerPro
​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021